Hypertension and Its Management in COVID-19 Patients: The Assorted View

Overview

Journal Int J Cardiol Cardiovasc Risk Prev

Specialty Cardiology & Vascular Diseases

Date 2021 Nov 22

PMID 34806090

Citations 23

Authors

Gaber El-Saber Batiha

Abdulrahim Gari

Norhan Elshony

Hazem M Shaheen

Murtala Bello Abubakar

Sherif Babatunde Adeyemi

Hayder M Al-Kuraishy

Affiliations

Soon will be listed here.

Abstract

Background: Coronavirus disease 2019 (COVID-19) is suspected to mainly be more deleterious in patients with underlying cardiovascular diseases (CVD). There is a strong association between hypertension and COVID-19 severity. The binding of SARS-CoV-2 to the angiotensin-converting enzyme 2 (ACE2) leads to deregulation of the renin-angiotensin-aldosterone system (RAAS) through down-regulation of ACE2 with subsequent increment of the harmful Ang II serum levels and reduction of the protective Ang-(1-7). Both angiotensin receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACEIs) are commonly used to manage hypertension.

Objective: Objective was to illustrate the potential link between hypertension and COVID-19 regarding the role of angiotensin receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACEIs) in hypertensive patients with COVID-19.

Methods: We carried out comprehensive databases search from late December 2019 to early January 2021 by using online engines of Web of Science, Research gate, Scopus, Google Scholar, and PubMed for published and preprinted articles.

Results: The present study's findings showed that hypertension is regarded as an independent risk factor for COVID-19 severity. Both ACEIs and ARBs are beneficial in managing hypertensive patients.

Conclusion: This study concluded that hypertension increases COVID-19 severity due to underlying endothelial dysfunctions and coagulopathy. COVID-19 might augment the hypertensive complications due to down-regulation of ACE2. The use of ACEIs or ARBs might be beneficial in the management of hypertensive patients with COVID-19.

Citing Articles

Decrypting the Possible Mechanistic Role of Fenofibrate in Alzheimer's Disease and Type 2 Diabetes: The Truth and Mystery.

Alsaleem M, Al-Kuraishy H, Al-Gareeb A, Abdel-Fattah M, Alrouji M, Al-Harchan N J Cell Mol Med. 2025; 29(5):e70378.

PMID: 40040308 PMC: 11880132. DOI: 10.1111/jcmm.70378.

Anxiety and depression among hypertensive patients during the COVID-19 pandemic: A cross-sectional study from Kathmandu Metropolitan, Nepal.

K C D, Kaphle H, Shrestha D, Neupane N PLoS One. 2024; 19(7):e0308048.

PMID: 39074135 PMC: 11285924. DOI: 10.1371/journal.pone.0308048.

A Comparative Investigation of the Pulmonary Vasodilating Effects of Inhaled NO Gas Therapy and Inhalation of a New Drug Formulation Containing a NO Donor Metabolite (SIN-1A).

Olah A, Barta B, Ruppert M, Sayour A, Nagy D, Balint T Int J Mol Sci. 2024; 25(14).

PMID: 39063223 PMC: 11277253. DOI: 10.3390/ijms25147981.

The possible role furin and furin inhibitors in endometrial adenocarcinoma: A narrative review.

Al-Kuraishy H, Al-Maiahy T, Al-Gareeb A, Alexiou A, Papadakis M, Saad H Cancer Rep (Hoboken). 2023; 7(1):e1920.

PMID: 38018319 PMC: 10809206. DOI: 10.1002/cnr2.1920.

The role of SARS-CoV-2-mediated NF-κB activation in COVID-19 patients.

Zhou Q, Zhang L, Dong Y, Wang Y, Zhang B, Zhou S Hypertens Res. 2023; 47(2):375-384.

PMID: 37872376 PMC: 10838770. DOI: 10.1038/s41440-023-01460-2.

References

Wu Z, McGoogan J . Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020; 323(13):1239-1242. DOI: 10.1001/jama.2020.2648. View

Lopez-Reyes A, Martinez-Armenta C, Espinosa-Velazquez R, Vazquez-Cardenas P, Cruz-Ramos M, Palacios-Gonzalez B . NLRP3 Inflammasome: The Stormy Link Between Obesity and COVID-19. Front Immunol. 2020; 11:570251. PMC: 7662564. DOI: 10.3389/fimmu.2020.570251. View

Fernandez-Ruiz I . RAAS inhibitors do not increase the risk of COVID-19. Nat Rev Cardiol. 2020; 17(7):383. PMC: 7243952. DOI: 10.1038/s41569-020-0401-0. View

Katz M . Regardless of Age, Obesity and Hypertension Increase Risks With COVID-19. JAMA Intern Med. 2020; . DOI: 10.1001/jamainternmed.2020.5415. View

Nurdiantami Y, Watanabe K, Tanaka E, Pradono J, Anme T . Association of general and central obesity with hypertension. Clin Nutr. 2017; 37(4):1259-1263. DOI: 10.1016/j.clnu.2017.05.012. View

Peng Y, Meng K, Guan H, Leng L, Zhu R, Wang B . [Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV]. Zhonghua Xin Xue Guan Bing Za Zhi. 2020; 48(6):450-455. DOI: 10.3760/cma.j.cn112148-20200220-00105. View

Yang J, Hu J, Zhu C . Obesity aggravates COVID-19: A systematic review and meta-analysis. J Med Virol. 2020; 93(1):257-261. PMC: 7361606. DOI: 10.1002/jmv.26237. View

Zhang P, Zhu L, Cai J, Lei F, Qin J, Xie J . Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19. Circ Res. 2020; 126(12):1671-1681. PMC: 7265882. DOI: 10.1161/CIRCRESAHA.120.317134. View

Tadic M, Saeed S, Grassi G, Taddei S, Mancia G, Cuspidi C . Hypertension and COVID-19: Ongoing Controversies. Front Cardiovasc Med. 2021; 8:639222. PMC: 7925389. DOI: 10.3389/fcvm.2021.639222. View

10.

Gao C, Cai Y, Zhang K, Zhou L, Zhang Y, Zhang X . Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study. Eur Heart J. 2020; 41(22):2058-2066. PMC: 7314067. DOI: 10.1093/eurheartj/ehaa433. View

11.

Liu X, Long C, Xiong Q, Chen C, Ma J, Su Y . Association of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with risk of COVID-19, inflammation level, severity, and death in patients with COVID-19: A rapid systematic review and meta-analysis. Clin Cardiol. 2020; . PMC: 7436520. DOI: 10.1002/clc.23421. View

12.

Dhall A, Patiyal S, Sharma N, Usmani S, Raghava G . Computer-aided prediction and design of IL-6 inducing peptides: IL-6 plays a crucial role in COVID-19. Brief Bioinform. 2020; 22(2):936-945. PMC: 7665369. DOI: 10.1093/bib/bbaa259. View

13.

Diaz J . Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19. J Travel Med. 2020; 27(3). PMC: 7184445. DOI: 10.1093/jtm/taaa041. View

14.

Michalakis K, Ilias I . SARS-CoV-2 infection and obesity: Common inflammatory and metabolic aspects. Diabetes Metab Syndr. 2020; 14(4):469-471. PMC: 7189186. DOI: 10.1016/j.dsx.2020.04.033. View

15.

Al-Kuraishy H, Al-Gareeb A . Effect of orlistat alone or in combination with on visceral adiposity index in obese patients. J Intercult Ethnopharmacol. 2016; 5(4):408-414. PMC: 5061485. DOI: 10.5455/jice.20160815080732. View

16.

Gue Y, Gorog D . Reduction in ACE2 may mediate the prothrombotic phenotype in COVID-19. Eur Heart J. 2020; 41(33):3198-3199. PMC: 7454491. DOI: 10.1093/eurheartj/ehaa534. View

17.

Cava E, Neri B, Carbonelli M, Riso S, Carbone S . Obesity pandemic during COVID-19 outbreak: Narrative review and future considerations. Clin Nutr. 2021; 40(4):1637-1643. PMC: 7923945. DOI: 10.1016/j.clnu.2021.02.038. View

18.

Remuzzi A, Remuzzi G . COVID-19 and Italy: what next?. Lancet. 2020; 395(10231):1225-1228. PMC: 7102589. DOI: 10.1016/S0140-6736(20)30627-9. View

19.

Ciavarella C, Motta I, Valente S, Pasquinelli G . Pharmacological (or Synthetic) and Nutritional Agonists of PPAR-γ as Candidates for Cytokine Storm Modulation in COVID-19 Disease. Molecules. 2020; 25(9). PMC: 7248959. DOI: 10.3390/molecules25092076. View

20.

Lippi G, Wong J, Henry B . Hypertension in patients with coronavirus disease 2019 (COVID-19): a pooled analysis. Pol Arch Intern Med. 2020; 130(4):304-309. DOI: 10.20452/pamw.15272. View